Opinion

Video

Final Thoughts on CSPC

Author(s):

Stephen J. Freedland, MD,Eleni Efstathiou, MD, PhD

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Video content above is prompted by the following questions:

  • How do you foresee the early treatment paradigm for CSPC evolving in the coming years?
    • Are there other novel agents you're excited about in development?
    • How will their availability impact treatment sequencing strategies?
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Bertram Yuh, MD, MISM, MSHCPM
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Oliver Sartor, MD
October 23rd 2024

177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center
June 20th 2024

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

Fred Saad, MD, FRCS
October 17th 2024

ARANOTE Data Highlight Darolutamide Plus ADT as a Potential Chemo-Free Option in mHSPC

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Darolutamide Plus ADT in mHSPC: © vitanovski - stock.adobe.com
October 14th 2024

EU Approval Sought for Darolutamide Plus ADT for mHSPC

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.
October 12th 2024

The OncFive: Top Oncology Articles for the Week of 10/6